Quell is harnessing the full power of Tregs, known as the “master modulators” of immune homeostasis, to create novel cell therapies designed to suppress overactive immune responses, drive long-term tolerance in the local immune environment and promote tissue repair. Quell’s versatile platform technology enables the Company to design, engineer and manufacture at scale, therapeutic Treg products with greater stability, persistence and potency than earlier generations. Key elements of this technology include its proprietary Phenotype-Lock technology, which enables Quell to “lock” Tregs in an immunosuppressive phenotype that enhances their safety, stability, and efficacy; chimeric antigen receptor (CAR) modules for tissue targeting; and additional modules to enhance disease-specific efficacy and safety.
Tanel Ozdemir, Investor at UCLTF said, "First and foremost, I'd like to highlight just how much of an impressive job the entire Quell team have done since being spun out from UCL, King's College London (KCL), and Hanover Medical School in 2019. The fact that they will begin patient recruitment for QEL-001 by the end of 2021 is a testament to this and further demonstrates the Company's pioneering role within the engineering Treg field. This latest $156m Series B financing is another laudable achievement by the team, and UCL Technology Fund (UCLTF) are delighted to see such a high quality and experienced set of new investors join us on this exciting journey ahead."